Aptadir Therapeutics raises EUR 40 million seed round with CDP Venture Capital backing

By Public Technologies
  • Aptadir Therapeutics closed a seed financing round of EUR 40 million, billed as Italy’s largest biotech seed round.
  • CDP Venture Capital participated via its Digital Transition Fund, alongside lead investor 4BIO Capital.
  • Proceeds target development of RNA inhibitor therapeutics, led by CAP1-FMR1 for Fragile X Syndrome, ahead of clinical work.
  • Aptadir develops DNMTs Interacting RNAs designed to reverse abnormal gene silencing implicated in cancers and genetic disorders.
  • EXTEND, the Italian technology transfer hub initiated by CDP Venture Capital, also made a follow-on investment from its pre-seed stake.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cdp Venture Capital Sgr SpA published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.